24/7 Market News Snapshot 05 June, 2025 – Silo Pharma, Inc. Common Stock (NASDAQ:SILO)
DENVER, Colo., 05 June, 2025 (www.247marketnews.com) – (Nasdaq:SILO) are discussed in this article.
Silo Pharma, Inc. (Nasdaq:SILO) is demonstrating notable momentum with its stock price recently rising to $0.643 in pre-market trading, marking an impressive increase of approximately 12.61% from the previous close of $0.571. This surge is indicative of strong investor interest, as evidenced by a trading volume of 9.74 million shares. Technical indicators suggest heightened buying activity, reinforcing a bullish outlook for the company. Market analysts and investors are advised to keep an eye on key resistance levels around $0.65 and support levels near $0.60 to better understand potential price developments.
In an effort to bolster its financial strategy, Silo Pharma’s Board of Directors has approved the purchase of up to $1 million in Bitcoin as a treasury reserve asset. CEO Eric Weisblum emphasized that this decision underscores the company’s commitment to diversifying its assets with digital currencies, which are perceived to carry considerable long-term value. By incorporating Bitcoin into its financial reserves, Silo aims to hedge against inflation risks while enhancing overall financial stability and fostering conditions for growth. This move aligns with the company’s objective of preserving and optimizing shareholder value over the long term.
Silo Pharma continues to tackle the needs of underserved patient populations, focusing on conditions such as stress-induced psychiatric disorders, chronic pain, and central nervous system ailments. The company’s portfolio includes advanced therapeutic programs targeting PTSD and fibromyalgia, in addition to preclinical efforts directed at Alzheimer’s disease and multiple sclerosis. Collaborations with prominent universities and research institutions play a significant role in Silo’s innovative drug development endeavors. As the company pursues growth opportunities and expands its impact, the strategic inclusion of Bitcoin reflects a progressive approach to asset management and long-term business objectives.
Related news for (SILO)
- Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.
- Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears
- Silo Pharma Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset
- MoBot alert highlights: NASDAQ: ZENA, NASDAQ: ZJK, NASDAQ: KRON, NASDAQ: SILO, NASDAQ: TGL (06/05/25 08:00 AM)